Malcolm A. Martin

Active 1971–2024

Also published as
MALCOLM A. MARTIN
82
Papers
18,429
Citations
73
h-index
82
i10-index

Citations

Citations per year for Malcolm A. Martin1971: 3 citations1972: 12 citations1973: 20 citations1974: 32 citations1975: 15 citations1976: 16 citations1977: 22 citations1978: 17 citations1979: 21 citations1980: 24 citations1981: 27 citations1982: 13 citations1983: 13 citations1984: 12 citations1985: 29 citations1986: 45 citations1987: 70 citations1988: 110 citations1989: 137 citations1990: 124 citations1991: 115 citations1992: 119 citations1993: 120 citations1994: 108 citations1995: 135 citations1996: 120 citations1997: 121 citations1998: 128 citations1999: 141 citations2000: 133 citations2001: 118 citations2002: 137 citations2003: 123 citations2004: 148 citations2005: 118 citations2006: 158 citations2007: 146 citations2008: 101 citations2009: 154 citations2010: 112 citations2011: 118 citations2012: 100 citations2013: 96 citations2014: 106 citations2015: 100 citations2016: 134 citations2017: 97 citations2018: 100 citations2019: 340 citations2020: 278 citations2021: 229 citations2022: 134 citations2023: 112 citations2024: 192 citations2025: 92 citations2026: 4 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,091 citing papers, 56.2% of this breakdownUnited Kingdom: 307 citing papers, 5.6% of this breakdownFrance: 268 citing papers, 4.9% of this breakdownGermany: 228 citing papers, 4.1% of this breakdownCanada: 166 citing papers, 3% of this breakdownNetherlands: 165 citing papers, 3% of this breakdownChina: 110 citing papers, 2% of this breakdownJapan: 108 citing papers, 2% of this breakdownSwitzerland: 101 citing papers, 1.8% of this breakdownItaly: 97 citing papers, 1.8% of this breakdownAustralia: 93 citing papers, 1.7% of this breakdownSouth Africa: 86 citing papers, 1.6% of this breakdown
0%56.2%Other 12.3%

Fields

  • Immunology and Microbiology69.9%
  • Medicine14.6%
  • Biochemistry, Genetics and Molecular Biology11.6%
  • Agricultural and Biological Sciences1.4%
  • Neuroscience1.1%
  • Environmental Science0.4%
  • Other1%

Topics

  • HIV Research and Treatment24.7%
  • Immune Cell Function and Interaction8.4%
  • HIV/AIDS drug development and treatment8.3%
  • HIV/AIDS Research and Interventions4.8%
  • T-cell and B-cell Immunology3.1%
  • Cytomegalovirus and herpesvirus research3%
  • Other47.7%

Coauthors

All papers

Open in search
  1. Early antibody therapy can induce long-lasting immunity to SHIV

    Authors: , , , , , , , , , , , , , , , , , , - Nature 2017 cited by 317

  2. Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pamela J. Björkman, Michel C. Nussenzweig - Nature 2019 cited by 201

  3. Detection of AIDS Virus in Macrophages in Brain Tissue from AIDS Patients with Encephalopathy

    Authors: , , , , , , , , , - Science 1986 cited by 1,699

  4. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia

    Authors: , , , , , , , , , , , , - Nature 2013 cited by 457

  5. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques

    Authors: , , , , , , , , , , , , , , , , , , , , - The Journal of Experimental Medicine 2014 cited by 335

  6. Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Science Translational Medicine 2021 cited by 63

  7. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges

    Authors: , , , , , , , , , , , , , , , - Nature 2016 cited by 307

  8. A single injection of crystallizable fragment domain–modified antibodies elicits durable protection from SHIV infection

    Authors: , , , , , , , , , , - Nature Medicine 2018 cited by 118

  9. Analysis of immunoglobulin transcripts and hypermutation following SHIVAD8 infection and protein-plus-adjuvant immunization

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jenny McDowell, Casandra Montemayor, James C. Mullikin, Morgan Park, Nancy L. Riebow, Karen Schandler, Brian J. Schmidt, Christina Sison, Mal Stantripop, James W. Thomas, Pamela J. Thomas, Meg Vemulapalli, Alice Young, Martha Nason, Nicholas M. Valiante, Padma Malyala, Ennio De Gregorio, Susan W. Barnett, Manmohan Singh, Derek T. O’Hagan, Richard A. Koup, John R. Mascola, Malcolm A. Martin, Thomas B. Kepler, Daniel C. Douek, Lawrence Shapiro, Robert A. Seder - Nature Communications 2015 cited by 93

  10. Neutralizing antibodies induced in immunized macaques recognize the CD4-binding site on an occluded-open HIV-1 envelope trimer

    Authors: , , , , , , , , , , , - Nature Communications 2022 cited by 40

  11. Induction of durable remission by dual immunotherapy in SHIV-infected ART-suppressed macaques

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Science 2024 cited by 30

  12. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection

    Authors: , , , , , - Nature 2005 cited by 1,277

  13. Delineating Antibody Recognition in Polyclonal Sera from Patterns of HIV-1 Isolate Neutralization

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Science 2013 cited by 227

  14. Immunotherapy during the acute SHIV infection of macaques confers long-term suppression of viremia

    Authors: , , , , , , , , , , , - The Journal of Experimental Medicine 2020 cited by 50

  15. CD4 binding site immunogens elicit heterologous anti–HIV-1 neutralizing antibodies in transgenic and wild-type animals

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pamela J. Björkman - Science Immunology 2023 cited by 36

  16. Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication

    Authors: , , , , - Journal of Virology 1995 cited by 443

  17. Virion incorporation of envelope glycoproteins with long but not short cytoplasmic tails is blocked by specific, single amino acid substitutions in the human immunodeficiency virus type 1 matrix

    Authors: , - Journal of Virology 1995 cited by 318

  18. Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - PLoS Pathogens 2017 cited by 91

  19. Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections

    Authors: , , , , , , , , , , , , , , - PLoS Pathogens 2018 cited by 84

  20. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes.

    Authors: , , , , , , , , , - The Journal of Experimental Medicine 1988 cited by 781

  21. Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions

    Authors: , - Journal of Virology 1996 cited by 337

  22. Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys

    Authors: , , , , , , , , - Nature Medicine 1999 cited by 542

  23. A Novel Gene of HIV-1, vpu , and Its 16-Kilodalton Product

    Authors: , , - Science 1988 cited by 446

  24. Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4 + T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans

    Authors: , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2001 cited by 353